Clinical trial
Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or…
NCT00490880 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00490880 |
|---|---|
| Title | Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer |
| Official title | The Evaluation of Efficacy and Toxicity of Combined Treatment: Neoadjuvant Chemotherapy (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer Stage T2b-T3 NO/Nx M0 |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Drug, Procedure |
| Interventions | gemcitabine, cisplatin, radical cystectomy, radiotherapy |
| Enrollment | 2 |
| Start date | Nov 1, 2003 |
| Completion | Aug 1, 2004 |
| First posted | Jun 25, 2007 |
| Last update posted | Jun 25, 2007 |
| Countries | Poland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: